Neuropharmacology & Neurotherapeutics
Onasemnogene abeparvovec
May. 18, 2021
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
This axial T2-weighted MRI of a 42-year-old man with cerebrotendinous xanthomatosis shows bilateral hyperintense lesions involving the dentate nuclei and deep cerebellar white matter. Clinical presentation: He had a history of early-onset cataracts, cognitive difficulty, and gait instability. Examination revealed nasal speech, severe dysarthria, marked ataxia of limbs and gait, and bilateral Achilles tendon xanthomas. (Source: Islam M, Hoggard N, Hadjivassiliou M. Cerebrotendinous xanthomatosis: diversity of presentation and refining treatment with chenodeoxycholic acid. Cerebellum Ataxias 2021;8[1]:5. Creative Commons Attribution 4.0 International License.)